Influenza Related Illness/Influenza Virus
The influenza vaccine is less effective in the elderly. It is unknown whether influenza vaccination of nonelderly adults confers additional disease protection on the elderly population. In a large, nationwide sample of Medicare beneficiaries, influenza vaccination among adults aged 18–64 years was inversely associated with illnesses related to influenza in the elderly. This year, the global market for products used in the fight against influenza will be worth an estimated $5.5 billion, according to a new technical market research report, the Global Influenza Market, from BCC Research. Market revenue is forecast to increase at a five-year compound annual growth rate (CAGR) of 8% from 2013 to 2018, totaling nearly $6 billion in 2018.
Related Conference of Influenza Related Illness/Influenza Virus
Influenza Related Illness/Influenza Virus Conference Speakers
Recommended Sessions
- Infection Treatment and Prevention Control
- Infection Novel Therapies
- Surveillance Practice for MRSA
- Antibiotics
- Control of HIV/AIDS from STDs & STIs
- Control of Infections during Pregnancy
- Control of Organs Transplatantation Infection
- Control of Zika/Malaria/Dengue Viral Infections
- Disinfecting with UV Technology
- Food and Drug Administration
- Fungal Infections/Germs
- Hand hygiene
- Health care
- Hepatitis C
- Infection by Zoonosis
- Infection care
- Infection control
- Infection control from Plants
- Infection Control in Intravenous Therapy/Physical Therapy
- Infection Control Products/Infection Rates
- Infection prevention
- Infection prophylaxis
- Infection therapies
- Infection treatment
- Influenza Related Illness/Influenza Virus
- Pediatric Infections Prevention and Control
- Practices and Awareness of Infection Control
- Rabies/Ebola Viral Infections Control
- Resistance and Emerging Infectious Organisms
- Respiratory and Pulmonary Infections Prevention and Control
- Smallpox/ Chickenpox Infection Control
- Surgical Infections Control
- Vaccination